UK Markets close in 7 hrs 31 mins
  • FTSE 100

    7,915.17
    +50.46 (+0.64%)
     
  • FTSE 250

    20,349.93
    +160.93 (+0.80%)
     
  • AIM

    881.63
    +2.50 (+0.28%)
     
  • GBP/EUR

    1.1239
    +0.0010 (+0.09%)
     
  • GBP/USD

    1.2085
    +0.0033 (+0.2743%)
     
  • BTC-GBP

    19,198.32
    +169.59 (+0.89%)
     
  • CMC Crypto 200

    534.99
    +9.04 (+1.72%)
     
  • S&P 500

    4,164.00
    +52.92 (+1.29%)
     
  • DOW

    34,156.69
    +265.67 (+0.78%)
     
  • CRUDE OIL

    77.74
    +0.60 (+0.78%)
     
  • GOLD FUTURES

    1,895.00
    +10.20 (+0.54%)
     
  • NIKKEI 225

    27,606.46
    -79.01 (-0.29%)
     
  • HANG SENG

    21,283.52
    -15.18 (-0.07%)
     
  • DAX

    15,401.56
    +80.68 (+0.53%)
     
  • CAC 40

    7,160.90
    +28.55 (+0.40%)
     

Voting Rights and Shares Capital of the Company

Nanobiotix S.A.
Nanobiotix S.A.

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, Jan. 11, 2023 (GLOBE NEWSWIRE) --

Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date

Number of Shares Outstanding

Total number of voting rights

Total voting rights, theoretical1

Total voting rights, exercisable2

December 31, 2022

34,875,872

36,287,449

36,265,331

As a reminder, Nanobiotix has announced on December 21, 2022, that it has ended the liquidity contract signed on October 23, 2012, with Gilbert Dupont. The termination is effective from December 20, 2022, after the close of Euronext market.

According to the article L.233-8 II of the French Commercial Code, Nanobiotix will make a new monthly publication of the total number of voting rights and shares comprising Nanobiotix’s capital if those figures differ from the information previously disclosed.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

____________________________

1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

2 The total number of exercisable at a Shareholders’ Meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

Contacts

Nanobiotix


Nanobiotix Communications
Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com


Nanobiotix Investor Relations
Kate McNeil
SVP, Investor Relations
+1 (609) 678-7388
investors@nanobiotix.com

Media Relations


France –
Ulysse Communication
Pierre-Louis Germain
+ 33 (0) 6 64 79 97 51
plgermain@ulysse-communication.com


US - LifeSci Advisors 
Ligia Vela-Reid 
+44 (0) 7413825310 
lvela-reid@lifesciadvisors.com

Attachment